Passiflora quadrangularis L. prevents experimental hypertension and vascular remodelling in rats exposed to nitric oxide deficit

Authors

DOI:

https://doi.org/10.17533/udea.vitae.v24n3a04

Keywords:

Isolated organ, hypertension, L-NAME, Passiflora quadrangularis L., vascular remodelling

Abstract


Background: Passiflora quadrangularis L. is among the species used in Colombian folk medicine for hypertension, but until now it has not been studied in experimental models. Objectives: To assess the capacity of P. quadrangularis L. EtOH extract to prevent the hypertension and vascular remodelling induced by nitric oxide (NO) deficit in Wistar rats. Methods: The nitric oxide (NO) synthase inhibitor L-NAME (10 mg/kg, i.p (intraperitoneal), every 48h) was administered for seven weeks to the following groups of rats: P. quadrangularis L.75, 150 and 300 mg/kg/d, p.o. (oral route); enalapril as reference agent, 10 mg/kg/d, p.o. and vehicle as control (mixture of propylene glycol 10%, glycerine 10% and polysorbate 2%). Arterial blood pressure (BP) and heart rate (HR) were measured twice a week. After sacrifice, the aortic rings were isolated, contraction was triggered with phenylephrine (PE 10-6 M) and then the relaxant response achieved with cumulative concentrations of acetylcholine (ACh, 10-10 – 10-5 M) or sodium nitroprusside (SNP, 10-10 – 10-5 M) was assessed. Histopathologic measures of thickness/lumen ratio from both the left ventricle and aorta walls, as well as phytochemical screening, were also performed. Results: As for enalapril, all doses of P. quadrangularis L. prevented the hypertension induced by L-NAME (122±1.2 versus 155±1.3 mmHg at seventh week). P. quadrangularis L. significantly increased the relaxant effect induced by ACh in isolated aorta and decreased the thickness/lumen ratio of aorta wall specimens. Conclusions: P. quadrangularis L. prevents experimental hypertension induced in rats with nitric oxide deficits improving the endothelium vasodilatation response and protecting against vascular remodelling.

|Abstract
= 142 veces | PDF
= 158 veces|

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Lesly L. BAREÑO, Universidad Nacional de Colombia

Faculty of Sciences, Department of Pharmacy

Pilar PUEBLA, Universidad del Tolima

Faculty of Sciences, Department of Pharmacy

Carlos M. GUERRA, Universidad de Caldas

Basic Sciences Department

Arturo SAN FELICIANO, Universidad de Salamanca

Faculty of Pharmacy, Department of Pharmaceutical Sciences

Gustavo ISAZA, Universidad de Caldas

Basic Sciences Department

Mario F. GUERRERO, Universidad Nacional de Colombia

Faculty of Sciences, Department of Pharmacy

References

Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015 Aug; 386(9995):801-12.

Sarki AM, Nduka CU, Stranges S, Kandala NB, Uthman OA. Prevalence of Hypertension in Low- and Middle-Income Countries. Medicine. 2015 Dec; 94(50):e1959.

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016 Aug;134(6):441-50.

Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J. 2016 Jul 11;38(15):ehw303.

Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011 Apr;86(4):304-14.

Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta - Gen Subj. 2013; 1830(6):3670-95.

Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. In: Li EC, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014

Wiysonge CS, Opie LH. β-Blockers as Initial Therapy for Hypertension. JAMA. 2013 Nov; 310(17):1851.

Moser M. Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. Am J Cardiol. 1989 Jan ;63(4):2B-7B.

Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010 Dec 21; 122(25):2727-35.

Kopincová J, Púzserová A, Bernátová I. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012; 64(3):511-20.

Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels. 2011 Nov; 26(6):628-36.

Nippon M. Angiotensin converting enzyme and aldosereductase inhibitory agent comprises Passiflora quadrangularis extract with organic solvent, water or vitexin. 1995-009562, 1993. 2p.

Sui H, Yu Q, Zhi Y, Geng G, Liu H, Xu H. [Effects of apigenin on the expression of angiotensin-converting enzyme 2 in kidney in spontaneously hypertensive rats]. Wei Sheng Yan Jiu. 2010 Nov; 39(6):693-6, 700.

Ramaiya SD, Bujang JS, Zakaria MH. Assessment of total phenolic, antioxidant, and antibacterial activities of Passiflora species. ScientificWorldJournal. 2014; 2014:167309.

de Castro PCF, Hoshino A, da Silva JC, Mendes FR. Possible anxiolytic effect of two extracts of Passiflora quadrangularis L. in experimental models. Phytother Res. 2007 May; 21(5):481-4.

Gazola AC, Costa GM, Castellanos L, Ramos FA, Reginatto FH, Lima TCM De, et al. Involvement of GABAergic pathway in the sedative activity of apigenin, the main flavonoid from Passiflora quadrangularis pericarp. Rev Bras Farmacogn. 2015; 25(2):158-63.

Avula B, Wang Y-H, Rumalla C, Smillie TJ, Khan IA. Simultaneous Determination of Alkaloids and Flavonoids from Aerial Parts os Passiflora Species and Dietary Supplements using UPLC-UV-MS and HPTLC. Narural Prod Commun. 2012; 7:1177-80.

Zucolotto SM, Fagundes C, Reginatto FH, Ramos FA, Castellanos L, Duque C, et al. Analysis of C-glycosyl flavonoids from South American Passiflora species by HPLC-DAD and HPLCMS. Phytochem Anal. 2012;23(3):2329.

Costa GM, Gazola AC, Zucolotto SM, Castellanos L, Ramos FA, Reginatto FH, et al. Chemical profiles of traditional preparations of four South American Passiflora species by chromatographic and capillary electrophoretic techniques. Rev Bras Farmacogn. 2016; 26(4):451-8.

Orsini F, Pelizzoni F, Verotta L. Quadranguloside a cycloartane triterpene glycoside from Passiflora quadrangularis. Phytochemistry. 1985; 25(1):191-

Downloads

Published

2017-12-19

How to Cite

BAREÑO, L. L., PUEBLA, P., GUERRA, C. M., SAN FELICIANO, A., ISAZA, G., & GUERRERO, M. F. (2017). Passiflora quadrangularis L. prevents experimental hypertension and vascular remodelling in rats exposed to nitric oxide deficit. Vitae, 24(3), 186–195. https://doi.org/10.17533/udea.vitae.v24n3a04

Issue

Section

Pharmacology and Toxicology

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.